Rank,Term name,P-value,Z-score,Combined score,Overlapping genes,Adjusted p-value,Old p-value,Old adjusted p-value,gene count
1,Differentiation Pathway WP2848,2.9499761686010827e-05,10.91497809419496,113.8555376900286,"['NT5E', 'NOTCH1', 'CSF1', 'EGF', 'HGF', 'WNT7B', 'VEGFA']",0.011976903244520396,0,0,7
2,Gene regulatory network modelling somitogenesis  WP2854,0.00028938970625235166,22.782608695652176,185.62668818975925,"['LFNG', 'NOTCH1', 'HES1', 'TBX6']",0.05874611036922739,0,0,4
3,The Overlap Between Signal Transduction Pathways that Contribute to a Range of LMNA Laminopathies WP4879,0.0007003997262453738,4.29154078549849,31.173148653814607,"['CEBPB', 'NOTCH1', 'MAOB', 'CEBPD', 'WNT7B', 'HMGA2', 'TNFRSF11B', 'HES1', 'HES5']",0.0947874296185406,0,0,9
4,NOTCH1 regulation of endothelial cell calcification WP3413,0.0015176407335696898,11.388305847076461,73.91691855864232,"['NOTCH1', 'SAT1', 'FGFR3', 'VEGFA']",0.13273637460256807,0,0,4
5,Globo Sphingolipid Metabolism WP1424,0.0018483192273888755,7.124624624624625,44.83867245555062,"['ST6GAL1', 'ST6GAL2', 'ST8SIA1', 'FUT2', 'A4GALT']",0.13273637460256807,0,0,5
6,Osteoblast differentiation WP4787,0.001961621299545341,3.098087431693989,19.313427337363088,"['HES6', 'SMAD1', 'NOTCH1', 'FGF9', 'WNT7B', 'SMAD9', 'PIK3CD', 'WNT7A', 'PRKCQ', 'PIK3C2A', 'FGFR3']",0.13273637460256807,0,0,11
7,Somitogenesis in the context of spondylocostal dysostosis WP4785,0.0030132848546357716,17.061377245508982,99.03659418407102,"['LFNG', 'NOTCH1', 'TBX6']",0.166830473031233,0,0,3
8,Neural Crest Differentiation WP2064,0.00442489221547109,3.149361859547444,17.071145434253914,"['SMAD1', 'NOTCH1', 'DCT', 'HES1', 'TBX6', 'ETS1', 'FGFR3', 'HES5', 'GFAP']",0.166830473031233,0,0,9
9,Endochondral Ossification with Skeletal Dysplasias WP4808,0.004433389311280923,3.866255343956471,20.949656046640275,"['SERPINH1', 'COL10A1', 'SLC38A2', 'FGFR3', 'IGF1R', 'DDR2', 'VEGFA']",0.166830473031233,0,0,7
10,Endochondral Ossification WP474,0.004433389311280923,3.866255343956471,20.949656046640275,"['SERPINH1', 'COL10A1', 'SLC38A2', 'FGFR3', 'IGF1R', 'DDR2', 'VEGFA']",0.166830473031233,0,0,7
11,Transcription factor regulation in adipogenesis WP3599,0.0045200374466590225,7.590204897551224,40.98129994392558,"['CEBPB', 'CEBPD', 'IRS1', 'IRS2']",0.166830473031233,0,0,4
12,NRF2 pathway WP2884,0.006039406714692134,2.6222222222222222,13.398112016726715,"['NQO1', 'HSP90AA1', 'SLC5A9', 'SRXN1', 'HGF', 'SLC39A11', 'GCLM', 'SLC6A1', 'SLC5A3', 'EPHA3', 'HSPA1A']",0.18111043424693696,0,0,11
13,Nucleotide-binding Oligomerization Domain (NOD) pathway WP1433,0.0062451873878254125,5.026938703409292,25.51646000242405,"['HSP90AA1', 'ACAP1', 'IL18', 'ERBIN', 'NOD1']",0.18111043424693696,0,0,5
14,Vitamin A and carotenoid metabolism WP716,0.0062451873878254125,5.026938703409292,25.51646000242405,"['RBP2', 'RBP1', 'BCO1', 'RXRG', 'RLBP1']",0.18111043424693696,0,0,5
15,SARS-CoV-2 altering angiogenesis via NRP1 WP5065,0.008914770080277913,34.077727952167415,160.84843731471219,"['NRP1', 'VEGFA']",0.2412931101728555,0,0,2
16,Apoptosis Modulation by HSP70 WP384,0.010072966971786782,5.691154422788606,26.167358811909406,"['CASP6', 'FAS', 'TNFRSF1A', 'HSPA1A']",0.2556015369090896,0,0,4
17,Nuclear Receptors Meta-Pathway WP2882,0.01195767696851543,1.9002997021768337,8.411451983437312,"['NQO1', 'HSP90AA1', 'SRXN1', 'HGF', 'SLC39A11', 'IRS2', 'DBI', 'SLC6A1', 'SLC5A3', 'CYP3A7', 'SLC5A9', 'SPINK13', 'HES1', 'SPRY1', 'GCLM', 'EPHA3', 'SLC19A2', 'HSPA1A']",0.25622069898527305,0,0,18
18,Complement and Coagulation Cascades WP558,0.012603634218536547,5.252912005535694,22.97502934466769,"['C1R', 'PROS1', 'SERPING1', 'KLKB1']",0.25622069898527305,0,0,4
19,Monoamine Transport WP727,0.012603634218536547,5.252912005535694,22.97502934466769,"['IL1R1', 'TNFRSF11B', 'SLC6A1', 'FBXO32']",0.25622069898527305,0,0,4
20,Notch Signaling WP268,0.013476364894035855,3.4195488721804512,14.727374212200735,"['LFNG', 'NUMBL', 'NOTCH1', 'DTX3L', 'HES1', 'HES5']",0.25622069898527305,0,0,6
21,IL17 signaling pathway WP2112,0.015228906646749455,3.8827463827463826,16.247584831019193,"['CEBPB', 'CEBPD', 'IL17RE', 'MAP3K14', 'IL17RB']",0.25622069898527305,0,0,5
22,The influence of laminopathies on Wnt signaling WP4844,0.015228906646749455,3.8827463827463826,16.247584831019193,"['CEBPB', 'CEBPD', 'HMGA2', 'HES1', 'HES5']",0.25622069898527305,0,0,5
23,Eicosanoid Synthesis WP167,0.015293592910897295,7.30945252352438,30.555860092118966,"['PNPLA3', 'ALOX12', 'PLA2G5']",0.25622069898527305,0,0,3
24,Hypertrophy Model WP516,0.015293592910897295,7.30945252352438,30.555860092118966,"['IL1R1', 'IL18', 'VEGFA']",0.25622069898527305,0,0,3
25,"Non-genomic actions of 1,25 dihydroxyvitamin D3 WP4341",0.01603738410836495,2.9206949750220392,12.070743919591767,"['PLCG2', 'PLCE1', 'PRKCQ', 'ETS1', 'RXRG', 'IFI44L', 'TNFRSF1A']",0.25622069898527305,0,0,7
26,Adipogenesis WP236,0.01640822210250517,2.347418813338031,9.647827290095655,"['SOCS3', 'CEBPB', 'KLF6', 'CEBPD', 'IRS1', 'PNPLA3', 'ID3', 'FAS', 'IRS2', 'RXRG']",0.25622069898527305,0,0,10
27,Apoptosis Modulation and Signaling WP1772,0.01903020856139798,2.5833404479353423,10.234491251266757,"['CASP6', 'IL1R1', 'BAG3', 'FAS', 'TNFRSF11B', 'MAP3K14', 'TNFRSF1A', 'HSPA1A']",0.27301429591922677,0,0,8
28,Differentiation of white and brown adipocyte WP2895,0.020173470141814785,6.395209580838324,24.96297728207388,"['SMAD1', 'CEBPB', 'SMAD9']",0.27301429591922677,0,0,3
29,Fatty acid transporters WP5061,0.020173470141814785,6.395209580838324,24.96297728207388,"['FABP3', 'ACSL6', 'DBI']",0.27301429591922677,0,0,3
30,Leptin Insulin Overlap WP3935,0.020173470141814785,6.395209580838324,24.96297728207388,"['SOCS3', 'IRS1', 'IRS2']",0.27301429591922677,0,0,3
31,Complement system WP2806,0.023454835045657565,3.415915915915916,12.818834625468398,"['C1R', 'PROS1', 'SERPING1', 'LAMB1', 'KLKB1']",0.3025841468978715,0,0,5
32,Genotoxicity pathway WP4286,0.024642360688419875,2.929752953813104,10.849719946333355,"['ARRDC4', 'ACTA2', 'ITPKC', 'DAAM1', 'CEBPD', 'PCDH8']",0.3025841468978715,0,0,6
33,Heart Development WP1591,0.026591288184551053,4.015521650939236,14.564986206706093,"['SMAD1', 'NOTCH1', 'NFATC1', 'VEGFA']",0.3025841468978715,0,0,4
34,Tryptophan metabolism WP465,0.026591288184551053,4.015521650939236,14.564986206706093,"['MAOB', 'AADAT', 'HAAO', 'DHCR24']",0.3025841468978715,0,0,4
35,Exercise-induced Circadian Regulation WP410,0.02744556936143649,2.8481203007518796,10.240560461577696,"['DNAJA1', 'CEBPB', 'RBPMS', 'PPP1R3C', 'TAB2', 'ETV6']",0.3025841468978715,0,0,6
36,BMP2-WNT4-FOXO1 pathway in primary endometrial stromal cell differentiation WP3876,0.027575402549806022,11.357249626307922,40.78196534564751,"['SMAD1', 'SMAD9']",0.3025841468978715,0,0,2
37,PTF1A related regulatory pathway WP4147,0.027575402549806022,11.357249626307922,40.78196534564751,"['NOTCH1', 'HES1']",0.3025841468978715,0,0,2
38,IL-4 signaling pathway WP395,0.03045167901182978,2.7709002235318025,9.674914418704484,"['SOCS3', 'CEBPB', 'IRS1', 'PIK3CD', 'FLNA', 'IRS2']",0.3238906758464325,0,0,6
39,Hematopoietic Stem Cell Differentiation WP2849,0.031112651128105583,3.792103948025987,13.15913445279691,"['HES6', 'NOTCH1', 'CSF1', 'TRIM29']",0.3238906758464325,0,0,4
40,Phytochemical activity on NRF2 transcriptional activation WP3,0.03219363085578459,5.115269461077844,17.575997556430565,"['NQO1', 'CEBPB', 'GCLM']",0.3267653531862136,0,0,3
41,Spinal Cord Injury WP2431,0.03682744731239861,2.242959226565784,7.405156490101417,"['LGALS3', 'ZFP36', 'VCAN', 'IL1R1', 'APEX1', 'XYLT1', 'PLA2G5', 'GFAP']",0.35788918413194903,0,0,8
42,Focal Adhesion-PI3K-Akt-mTOR-signaling pathway WP3932,0.03885057947850291,1.6673219746614243,5.415515605671465,"['IFNAR2', 'CRTC2', 'HSP90AA1', 'CSF1', 'CAB39L', 'IRS1', 'EGF', 'HGF', 'PIK3CD', 'IRS2', 'LAMB1', 'OSMR', 'PIK3C2A', 'VEGFA', 'IGF1R', 'FGF9', 'FGFR3']",0.35788918413194903,0,0,17
43,EGFR Tyrosine Kinase Inhibitor Resistance WP4806,0.0396427562644479,2.2065878460565367,7.122528046367046,"['MRAS', 'EGF', 'HGF', 'PLCG2', 'PIK3CD', 'FGFR3', 'IGF1R', 'VEGFA']",0.35788918413194903,0,0,8
44,Transcriptional cascade regulating adipogenesis WP4211,0.039856488669553665,8.517189835575486,27.446389237578,"['CEBPB', 'CEBPD']",0.35788918413194903,0,0,2
45,Interferon type I signaling pathways WP585,0.040730556256455996,2.562406015037594,8.201689469505073,"['IFNAR2', 'SOCS3', 'IRS1', 'PDCD4', 'PIK3CD', 'IRS2']",0.35788918413194903,0,0,6
46,Structural Pathway of Interleukin 1 (IL-1) WP2637,0.040730556256455996,2.562406015037594,8.201689469505073,"['IL1R1', 'IRAK2', 'IRF7', 'TAB2', 'IL1RAP', 'MAP3K14']",0.35788918413194903,0,0,6
47,Signal transduction through IL1R WP4496,0.0414305213157675,3.4122938530734634,10.863847696045166,"['IRAK2', 'IL1R1', 'IL1RAP', 'MAP3K14']",0.35788918413194903,0,0,4
48,MicroRNA for Targeting Cancer Growth and Vascularization in Glioblastoma WP3593,0.05377662239541602,6.813153961136024,19.9142796818434,"['HES1', 'VEGFA']",0.45262966939551813,0,0,2
49,Microglia Pathogen Phagocytosis Pathway WP3937,0.05574257012260076,3.933786273606633,11.356884829161563,"['PLCG2', 'PIK3CD', 'PIK3C2A']",0.45262966939551813,0,0,3
50,Photodynamic therapy-induced NFE2L2 (NRF2) survival signaling WP3612,0.05574257012260076,3.933786273606633,11.356884829161563,"['NQO1', 'SRXN1', 'GCLM']",0.45262966939551813,0,0,3
51,MAPK Signaling Pathway WP382,0.059190582994836524,1.594603230960412,4.507931885915257,"['IL1R1', 'DUSP1', 'EGF', 'HSPB1', 'NFATC1', 'TNFRSF1A', 'MRAS', 'FGF9', 'FLNA', 'FAS', 'TAB2', 'MAP3K6', 'FGFR3', 'MAP3K14', 'HSPA1B', 'HSPA1A']",0.46414616258997926,0,0,16
52,Vitamin D Receptor Pathway WP2877,0.05944729176029291,2.1355421686746987,6.027920587846107,"['CEACAM1', 'BCL6', 'S100A6', 'CD9', 'PRKCQ', 'TNFRSF11B', 'ATP2C2']",0.46414616258997926,0,0,7
53,Bladder cancer WP2828,0.06716976886719465,2.842578710644678,7.67647477266624,"['EGF', 'DAPK2', 'FGFR3', 'VEGFA']",0.4923013521870032,0,0,4
54,FGF23 signaling in hypophosphatemic rickets and related disorders WP4790,0.06911619969127877,5.677130044843049,15.169099236960857,"['FAM20C', 'FGFR3']",0.4923013521870032,0,0,2
55,"GPCRs, Class B Secretin-like WP334",0.06911619969127877,5.677130044843049,15.169099236960857,"['CALCRL', 'ADGRG2']",0.4923013521870032,0,0,2
56,Inflammatory Response Pathway WP453,0.06911619969127877,5.677130044843049,15.169099236960857,"['LAMB1', 'TNFRSF1A']",0.4923013521870032,0,0,2
57,RAS and bradykinin pathways in COVID-19 WP4969,0.06911619969127877,5.677130044843049,15.169099236960857,"['SERPING1', 'KLKB1']",0.4923013521870032,0,0,2
58,ESC Pluripotency Pathways WP3931,0.07148778827214157,1.92534998831602,5.079513475934407,"['SMAD1', 'FGF9', 'EGF', 'WNT7B', 'SMAD9', 'PIK3CD', 'WNT7A', 'FGFR3']",0.500414517904991,0,0,8
59,Ovarian infertility WP34,0.07488266596168397,3.408682634730539,8.834735608577605,"['CEBPB', 'MSH5', 'SYNE2']",0.5067060396740615,0,0,3
60,Type I interferon induction and signaling during SARS-CoV-2 infection WP4868,0.07488266596168397,3.408682634730539,8.834735608577605,"['IFIH1', 'IFNAR2', 'IRF7']",0.5067060396740615,0,0,3
61,Aryl Hydrocarbon Receptor Netpath WP2586,0.08251975034225657,2.623457502018222,6.544785645649217,"['NQO1', 'HSP90AA1', 'KLF6', 'VEGFA']",0.5130803959768504,0,0,4
62,Factors and pathways affecting insulin-like growth factor (IGF1)-Akt signaling WP3850,0.08251975034225657,2.623457502018222,6.544785645649217,"['IRS1', 'FBXO32', 'IGF1R', 'TNFRSF1A']",0.5130803959768504,0,0,4
63,PKC-gamma calcium signaling pathway in ataxia WP4760,0.08539868572533998,3.195359281437126,7.861940479439993,"['GNA14', 'GRM1', 'GRIA4']",0.5130803959768504,0,0,3
64,Zinc homeostasis WP3529,0.08539868572533998,3.195359281437126,7.861940479439993,"['SLC30A3', 'SLC39A11', 'SLC30A10']",0.5130803959768504,0,0,3
65,Dopamine metabolism WP2436,0.08567490473952584,4.8656843903480675,11.955936927662894,"['NQO1', 'MAOB']",0.5130803959768504,0,0,2
66,IL1 and megakaryocytes in obesity WP2865,0.08567490473952584,4.8656843903480675,11.955936927662894,"['IL1R1', 'IL18']",0.5130803959768504,0,0,2
67,Nicotine Activity on Dopaminergic Neurons WP1602,0.08567490473952584,4.8656843903480675,11.955936927662894,"['CHRNA4', 'ADCY2']",0.5130803959768504,0,0,2
68,Insulin Signaling WP481,0.08593464760203406,1.6163358942802863,3.966760125126299,"['SOCS3', 'SNAP25', 'XBP1', 'IRS1', 'PIK3CD', 'IRS2', 'PRKCQ', 'MAP3K6', 'PIK3C2A', 'MAP3K14', 'SH2B2', 'IGF1R']",0.5130803959768504,0,0,12
69,Amplification and Expansion of Oncogenic Pathways as Metastatic Traits WP3678,0.10327024930971367,4.257100149476831,9.665345496974485,"['NOTCH1', 'VEGFA']",0.5616466255971038,0,0,2
70,FOXA2 pathway WP5066,0.10327024930971367,4.257100149476831,9.665345496974485,"['IRS1', 'IRS2']",0.5616466255971038,0,0,2
71,ID signaling pathway WP53,0.10327024930971367,4.257100149476831,9.665345496974485,"['ID3', 'ELK3']",0.5616466255971038,0,0,2
72,Kynurenine Pathway and links to Cellular Senescence WP5044,0.10327024930971367,4.257100149476831,9.665345496974485,"['AADAT', 'HAAO']",0.5616466255971038,0,0,2
73,miR-509-3p alteration of YAP1/ECM axis WP3967,0.10327024930971367,4.257100149476831,9.665345496974485,"['EDNRA', 'TEAD3']",0.5616466255971038,0,0,2
74,Control of immune tolerance by vasoactive intestinal peptide WP4484,0.10808959020693337,17.013432835820897,37.851397869342165,['FAS'],0.5616466255971038,0,0,1
75,Intracellular trafficking proteins involved in CMT neuropathy WP4856,0.10815198237252423,2.839820359281437,6.316378983135511,"['HSPB8', 'HSPB1', 'NDRG1']",0.5616466255971038,0,0,3
76,NRF2-ARE regulation WP4357,0.10815198237252423,2.839820359281437,6.316378983135511,"['NQO1', 'CEBPB', 'GCLM']",0.5616466255971038,0,0,3
77,Ferroptosis WP4313,0.10843974082471695,2.3514449671715867,5.223877596513787,"['ACSL6', 'GCLM', 'SAT1', 'CP']",0.5616466255971038,0,0,4
78,Phosphoinositides metabolism WP4971,0.10843974082471695,2.3514449671715867,5.223877596513787,"['PLCG2', 'PIK3CD', 'PLCE1', 'PIK3C2A']",0.5616466255971038,0,0,4
79,Breast cancer pathway WP4262,0.11870086395367352,1.6351803046859934,3.48481237884593,"['NOTCH1', 'FGF9', 'EGF', 'WNT7B', 'PIK3CD', 'WNT7A', 'HES1', 'HES5', 'IGF1R']",0.5616466255971038,0,0,9
80,Aryl Hydrocarbon Receptor Pathway WP2873,0.12031609450994216,2.690119760479042,5.696686051893108,"['NQO1', 'HSP90AA1', 'HES1']",0.5616466255971038,0,0,3
81,"GPCRs, Other WP117",0.12031609450994216,2.690119760479042,5.696686051893108,"['EDNRA', 'GPR143', 'GRM1']",0.5616466255971038,0,0,3
82,Lung fibrosis WP3624,0.12031609450994216,2.690119760479042,5.696686051893108,"['CEBPB', 'EGF', 'HGF']",0.5616466255971038,0,0,3
83,Type I collagen synthesis in the context of Osteogenesis imperfecta WP4786,0.12031609450994216,2.690119760479042,5.696686051893108,"['SERPINH1', 'P3H2', 'TNFRSF11B']",0.5616466255971038,0,0,3
84,BMP Signaling Pathway in Eyelid Development WP3927,0.12173621441513581,3.7837568510214252,7.96820883063951,"['SMAD1', 'NOTCH1']",0.5616466255971038,0,0,2
85,Cancer immunotherapy by PD-1 blockade WP4585,0.12173621441513581,3.7837568510214252,7.96820883063951,"['NFATC1', 'PDCD1LG2']",0.5616466255971038,0,0,2
86,GDNF/RET signaling axis WP4830,0.12173621441513581,3.7837568510214252,7.96820883063951,"['IFT27', 'SPRY1']",0.5616466255971038,0,0,2
87,GPR40 Pathway WP3958,0.12173621441513581,3.7837568510214252,7.96820883063951,"['PLCG2', 'PLCE1']",0.5616466255971038,0,0,2
88,Tryptophan catabolism leading to NAD+ production WP4210,0.12173621441513581,3.7837568510214252,7.96820883063951,"['AADAT', 'HAAO']",0.5616466255971038,0,0,2
89,IL-1 signaling pathway WP195,0.13465064137327426,1.9376194376194376,3.885065892907697,"['IL1R1', 'IRAK2', 'TAB2', 'IL1RAP', 'MAP3K14']",0.607424004417215,0,0,5
90,p53 transcriptional gene network WP4963,0.13465064137327426,1.9376194376194376,3.885065892907697,"['NOTCH1', 'GLS2', 'SESN1', 'FAS', 'SAT1']",0.607424004417215,0,0,5
91,Cysteine and methionine catabolism WP4504,0.14092198764108765,3.4050822122571,6.672424833961718,"['BHMT', 'SQOR']",0.6218948585030607,0,0,2
92,Deregulation of Rab and Rab Effector Genes in Bladder Cancer WP2291,0.14092198764108765,3.4050822122571,6.672424833961718,"['SYTL4', 'TBC1D10A']",0.6218948585030607,0,0,2
93,Notch Signaling Pathway Netpath WP61,0.14322362133397432,1.8943943943943944,3.681467717841083,"['HES6', 'NUMBL', 'NOTCH1', 'HES1', 'HES5']",0.6219274552254479,0,0,5
94,Neovascularisation processes WP4331,0.14602970199065032,2.433490162532079,4.681901813993301,"['SMAD1', 'NOTCH1', 'SMAD9']",0.6219274552254479,0,0,3
95,Regucalcin in proximal tubule epithelial kidney cells WP4838,0.14602970199065032,2.433490162532079,4.681901813993301,"['ACTA2', 'PRKCQ', 'TNFRSF1A']",0.6219274552254479,0,0,3
96,IL-18 signaling pathway WP4754,0.14705673818138668,1.4240121580547112,2.729741298954827,"['CEBPB', 'NRN1', 'EPB41', 'HSPB8', 'IL18', 'HSPB1', 'TNFRSF11B', 'VEGFA', 'TNFRSF1A', 'ACTA2', 'SOCS3', 'FAS', 'KIFC3']",0.6219274552254479,0,0,13
97,Benzene metabolism WP3891,0.15767704828870266,8.50597014925373,15.712281953044654,['NQO1'],0.6459451540822316,0,0,1
98,Hypothetical Craniofacial Development Pathway WP3655,0.15767704828870266,8.50597014925373,15.712281953044654,['ARHGAP29'],0.6459451540822316,0,0,1
99,Metabolism of alpha-linolenic acid WP4586,0.15767704828870266,8.50597014925373,15.712281953044654,['ALOX12'],0.6459451540822316,0,0,1
100,Resistin as a regulator of inflammation WP4481,0.15950232792010743,2.32267283614589,4.263723003925489,"['PLCG2', 'PIK3CD', 'PLCE1']",0.6459451540822316,0,0,3
101,Extracellular vesicles in the crosstalk of cardiac cells WP4300,0.16069078956232855,3.0952575078135616,5.658976727387938,"['EGF', 'HSPB1']",0.6459451540822316,0,0,2
102,Apoptosis WP254,0.17028024061202623,1.7755255255255256,3.143230104798147,"['CASP6', 'IRF7', 'FAS', 'IGF1R', 'TNFRSF1A']",0.6617389733346544,0,0,5
103,Oncostatin M Signaling Pathway WP2374,0.17028024061202623,1.7755255255255256,3.143230104798147,"['SOCS3', 'CEBPB', 'IRS1', 'OSMR', 'VEGFA']",0.6617389733346544,0,0,5
104,GABA receptor Signaling WP4159,0.17333440914400414,2.2214917990106744,3.8932366862002135,"['GABRA2', 'GABRA5', 'SLC6A1']",0.6617389733346544,0,0,3
105,Proximal tubule transport WP4917,0.17333440914400414,2.2214917990106744,3.8932366862002135,"['SLC13A3', 'SLC1A1', 'SLC3A1']",0.6617389733346544,0,0,3
106,Glioblastoma signaling pathways WP2261,0.17573413302568505,1.64996361872423,2.8689287467419398,"['IRS1', 'PLCG2', 'PIK3CD', 'PRKCQ', 'PIK3C2A', 'IGF1R']",0.6617389733346544,0,0,6
107,ERK Pathway in Huntington's Disease WP3853,0.18091878335011488,2.8370702541106128,4.850559040870771,"['EGF', 'GRM1']",0.6617389733346544,0,0,2
108,NAD+ metabolism WP3644,0.18091878335011488,2.8370702541106128,4.850559040870771,"['NT5E', 'CD38']",0.6617389733346544,0,0,2
109,Nanomaterial induced apoptosis WP2507,0.18091878335011488,2.8370702541106128,4.850559040870771,"['CASP6', 'FAS']",0.6617389733346544,0,0,2
110,Photodynamic therapy-induced NF-kB survival signaling WP3617,0.18091878335011488,2.8370702541106128,4.850559040870771,"['VEGFA', 'TNFRSF1A']",0.6617389733346544,0,0,2
111,SARS coronavirus and innate immunity WP4912,0.18091878335011488,2.8370702541106128,4.850559040870771,"['IFIH1', 'IFNAR2']",0.6617389733346544,0,0,2
112,PPAR signaling pathway WP3942,0.19185650619660424,1.8417277847562705,3.0407064775467596,"['FABP3', 'ACSL6', 'DBI', 'RXRG']",0.6919305125790304,0,0,4
113,MFAP5 effect on permeability and motility of endothelial cells via cytoskeleton rearrangement WP4560,0.20149406203556833,2.618604116361964,4.1949916619888254,"['ACTN1', 'PRKCQ']",0.6919305125790304,0,0,2
114,Pregnane X receptor pathway WP2876,0.20149406203556833,2.618604116361964,4.1949916619888254,"['HSP90AA1', 'CYP3A7']",0.6919305125790304,0,0,2
115,Alpha 6 Beta 4 signaling pathway WP244,0.20192633607499072,2.0434131736526946,3.269159308602344,"['IRS1', 'IRS2', 'LAMB1']",0.6919305125790304,0,0,3
116,Blood Clotting Cascade WP272,0.20451148155045235,5.670149253731343,8.999270565704323,['KLKB1'],0.6919305125790304,0,0,1
117,Osteoblast Signaling WP322,0.20451148155045235,5.670149253731343,8.999270565704323,['TNFRSF11B'],0.6919305125790304,0,0,1
118,Robo4 and VEGF Signaling Pathways Crosstalk WP3943,0.20451148155045235,5.670149253731343,8.999270565704323,['VEGFA'],0.6919305125790304,0,0,1
119,Somatic sex determination WP4814,0.20451148155045235,5.670149253731343,8.999270565704323,['FGF9'],0.6919305125790304,0,0,1
120,The alternative pathway of fetal androgen synthesis WP4524,0.20451148155045235,5.670149253731343,8.999270565704323,['HSD17B6'],0.6919305125790304,0,0,1
121,Apoptosis-related network due to altered Notch3 in ovarian cancer WP2864,0.21523824934615865,1.7469726675123975,2.6833670116582944,"['SOCS3', 'NQO1', 'HSPB1', 'ETS1']",0.7051175218161021,0,0,4
122,Glucocorticoid Receptor Pathway WP2880,0.21523824934615865,1.7469726675123975,2.6833670116582944,"['HSP90AA1', 'SPINK13', 'SPRY1', 'SLC19A2']",0.7051175218161021,0,0,4
123,Mitochondrial Gene Expression WP391,0.22231570802717804,2.431347426863122,3.6559120894197425,"['CAMK4', 'TFB2M']",0.7051175218161021,0,0,2
124,Urea cycle and metabolism of amino groups WP497,0.22231570802717804,2.431347426863122,3.6559120894197425,"['ARG2', 'OAT']",0.7051175218161021,0,0,2
125,Head and Neck Squamous Cell Carcinoma WP4674,0.22951405597324318,1.5774107440774108,2.3216189447749844,"['NOTCH1', 'SESN1', 'FGFR3', 'IGF1R', 'VEGFA']",0.7051175218161021,0,0,5
126,TNF-alpha signaling pathway WP231,0.23740388582602526,1.4816606734226871,2.1306168302486435,"['HSP90AA1', 'OTUD7B', 'TAB2', 'RFFL', 'MAP3K14', 'TNFRSF1A']",0.7051175218161021,0,0,6
127,Angiogenesis WP1539,0.243292920048369,2.2690582959641254,3.2072892350795583,"['SMAD1', 'VEGFA']",0.7051175218161021,0,0,2
128,Canonical and non-canonical Notch signaling WP3845,0.243292920048369,2.2690582959641254,3.2072892350795583,"['NOTCH1', 'HES1']",0.7051175218161021,0,0,2
129,Mitochondrial CIV Assembly WP4922,0.2465897765384973,1.823994867408041,2.5536459779513216,"['COA3', 'COX14', 'PET117']",0.7051175218161021,0,0,3
130,Photodynamic therapy-induced AP-1 survival signaling. WP3611,0.2465897765384973,1.823994867408041,2.5536459779513216,"['HSP90AA1', 'FAS', 'TNFRSF1A']",0.7051175218161021,0,0,3
131,G Protein Signaling Pathways WP35,0.2467158303279395,1.4603651987110633,2.0438075123930477,"['GNA14', 'AKAP10', 'PRKCQ', 'ADCY2', 'AKAP5', 'PDE8B']",0.7051175218161021,0,0,6
132,Cytokines and Inflammatory Response WP530,0.24874551430083774,4.2522388059701495,5.916245884860106,['CSF1'],0.7051175218161021,0,0,1
133,Estrogen metabolism WP697,0.24874551430083774,4.2522388059701495,5.916245884860106,['NQO1'],0.7051175218161021,0,0,1
134,NAD Biosynthesis II (from tryptophan) WP2485,0.24874551430083774,4.2522388059701495,5.916245884860106,['HAAO'],0.7051175218161021,0,0,1
135,Role of Osx and miRNAs in tooth development WP3971,0.24874551430083774,4.2522388059701495,5.916245884860106,['NOTCH1'],0.7051175218161021,0,0,1
136,SARS-CoV-2 and COVID-19 Pathway WP4846,0.24874551430083774,4.2522388059701495,5.916245884860106,['NRP1'],0.7051175218161021,0,0,1
137,Serotonin Transporter Activity WP1455,0.24874551430083774,4.2522388059701495,5.916245884860106,['IL1R1'],0.7051175218161021,0,0,1
138,Somatroph axis (GH) and its relationship to dietary restriction and aging WP4186,0.24874551430083774,4.2522388059701495,5.916245884860106,['IGF1R'],0.7051175218161021,0,0,1
139,Ebola Virus Pathway on Host WP4217,0.25024782427049075,1.4033486888731397,1.9440639276684928,"['SOCS3', 'ACTN1', 'NEDD4', 'IRF7', 'PIK3CD', 'FLNA', 'IGF1R']",0.7051175218161021,0,0,7
140,Ebstein-Barr virus LMP1 signaling WP262,0.2643442031217662,2.1270553064275037,2.830053945680361,"['HSP90AA1', 'MAP3K14']",0.7051175218161021,0,0,2
141,FBXL10 enhancement of MAP/ERK signaling in diffuse large B-cell lymphoma WP4553,0.2643442031217662,2.1270553064275037,2.830053945680361,"['BCL6', 'H2AFZ']",0.7051175218161021,0,0,2
142,Metabolism of Spingolipids in ER and Golgi apparatus WP4142,0.2643442031217662,2.1270553064275037,2.830053945680361,"['UGT8', 'UGCG']",0.7051175218161021,0,0,2
143,Prostaglandin Synthesis and Regulation WP98,0.2643442031217662,2.1270553064275037,2.830053945680361,"['EDNRA', 'S100A6']",0.7051175218161021,0,0,2
144,Striated Muscle Contraction Pathway WP383,0.2643442031217662,2.1270553064275037,2.830053945680361,"['ACTA2', 'TCAP']",0.7051175218161021,0,0,2
145,Urea cycle and associated pathways WP4595,0.2643442031217662,2.1270553064275037,2.830053945680361,"['OAT', 'GLS2']",0.7051175218161021,0,0,2
146,White fat cell differentiation WP4149,0.2643442031217662,2.1270553064275037,2.830053945680361,"['CEBPB', 'CEBPD']",0.7051175218161021,0,0,2
147,Angiopoietin Like Protein 8 Regulatory Pathway WP3915,0.2676919087086061,1.3365273711294472,1.7614342205175941,"['SLCO1C1', 'IRS1', 'TRIP10', 'PIK3CD', 'IRS2', 'MAP3K6', 'PIK3C2A', 'MAP3K14']",0.7051175218161021,0,0,8
148,Calcium Regulation in the Cardiac Cell WP536,0.2676919087086061,1.3365273711294472,1.7614342205175941,"['RGS4', 'RGS17', 'PLN', 'GRK5', 'CAMK4', 'GJA9', 'PRKCQ', 'ADCY2']",0.7051175218161021,0,0,8
149,DNA damage response (only ATM dependent) WP710,0.27524021442852575,1.399979400556185,1.80612890225296,"['BCL6', 'IRS1', 'WNT7B', 'PIK3CD', 'WNT7A', 'PIK3C2A']",0.7051175218161021,0,0,6
150,PI3K-Akt signaling pathway WP4172,0.27686785189544216,1.2315096251266464,1.5815230785504373,"['IFNAR2', 'HSP90AA1', 'CSF1', 'IRS1', 'EGF', 'HGF', 'PIK3CD', 'LAMB1', 'OSMR', 'VEGFA', 'IGF1R', 'FGF9', 'FGFR3']",0.7051175218161021,0,0,13
151,Fas ligand pathway and stress induction of heat shock proteins WP314,0.27715058394604575,1.7020958083832336,2.184119632819945,"['CASP6', 'HSPB1', 'FAS']",0.7051175218161021,0,0,3
152,Metapathway biotransformation Phase I and II WP702,0.28491913419090087,1.3809388335704125,1.7338375849210426,"['CYP39A1', 'HS3ST3B1', 'CHST6', 'CHST7', 'KCNAB1', 'CYP3A7']",0.7051175218161021,0,0,6
153,Hippo-Yap signaling pathway WP4537,0.2853966169356062,2.0017585509540137,2.5099558593780804,"['NDRG1', 'TEAD3']",0.7051175218161021,0,0,2
154,Mammary gland development pathway - Pregnancy and lactation (Stage 3 of 4) WP2817,0.2853966169356062,2.0017585509540137,2.5099558593780804,"['CEBPB', 'ATP2C2']",0.7051175218161021,0,0,2
155,TYROBP causal network in microglia WP3945,0.2853966169356062,2.0017585509540137,2.5099558593780804,"['IL18', 'IL13RA1']",0.7051175218161021,0,0,2
156,Vitamin D in inflammatory diseases WP4482,0.2853966169356062,2.0017585509540137,2.5099558593780804,"['DUSP1', 'NFATC1']",0.7051175218161021,0,0,2
157,Aspirin and miRNAs WP4707,0.2905233239545531,3.401492537313433,4.204487700215934,['VEGFA'],0.7051175218161021,0,0,1
158,Biogenic Amine Synthesis WP550,0.2905233239545531,3.401492537313433,4.204487700215934,['PAH'],0.7051175218161021,0,0,1
159,Complement Activation WP545,0.2905233239545531,3.401492537313433,4.204487700215934,['C1R'],0.7051175218161021,0,0,1
160,Farnesoid X receptor pathway WP2879,0.2905233239545531,3.401492537313433,4.204487700215934,['IRS2'],0.7051175218161021,0,0,1
161,Folate-Alcohol and Cancer Pathway Hypotheses WP1589,0.2905233239545531,3.401492537313433,4.204487700215934,['CEBPB'],0.7051175218161021,0,0,1
162,Insulin signaling in adipocytes (diabetic condition) WP3635,0.2905233239545531,3.401492537313433,4.204487700215934,['IRS1'],0.7051175218161021,0,0,1
163,Insulin signaling in adipocytes (normal condition) WP3634,0.2905233239545531,3.401492537313433,4.204487700215934,['IRS1'],0.7051175218161021,0,0,1
164,LDLRAD4 and what we know about it WP4904,0.2905233239545531,3.401492537313433,4.204487700215934,['NEDD4'],0.7051175218161021,0,0,1
165,Mammary gland development pathway - Involution (Stage 4 of 4) WP2815,0.2905233239545531,3.401492537313433,4.204487700215934,['SOCS3'],0.7051175218161021,0,0,1
166,"Phase I biotransformations, non P450 WP136",0.2905233239545531,3.401492537313433,4.204487700215934,['PON1'],0.7051175218161021,0,0,1
167,Urea cycle and related diseases WP4571,0.2905233239545531,3.401492537313433,4.204487700215934,['GLS2'],0.7051175218161021,0,0,1
168,Nephrotic syndrome WP4758,0.2925714471863487,1.6470446204365463,2.0242942255683585,"['CUBN', 'PLCE1', 'COQ8B']",0.7051175218161021,0,0,3
169,Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways WP706,0.30280085346374974,1.3101251158480074,1.565180193287574,"['SNAP25', 'CEBPB', 'CHRNA4', 'PAH', 'HES1', 'HES5', 'VEGFA']",0.7051175218161021,0,0,7
170,Endothelin Pathways WP2197,0.30638507898083756,1.8903836571998007,2.2361585337862415,"['EDNRA', 'CALCRL']",0.7051175218161021,0,0,2
171,FGFR3 signaling in chondrocyte proliferation and terminal differentiation WP4767,0.30638507898083756,1.8903836571998007,2.2361585337862415,"['FGF9', 'FGFR3']",0.7051175218161021,0,0,2
172,Sphingolipid Metabolism (general overview) WP4725,0.30638507898083756,1.8903836571998007,2.2361585337862415,"['UGCG', 'UGT8']",0.7051175218161021,0,0,2
173,Unfolded protein response WP4925,0.30638507898083756,1.8903836571998007,2.2361585337862415,"['XBP1', 'TXNIP']",0.7051175218161021,0,0,2
174,Vitamin B12 metabolism WP1533,0.30638507898083756,1.8903836571998007,2.2361585337862415,"['SERPINA3', 'CUBN']",0.7051175218161021,0,0,2
175,SARS-CoV-2 innate immunity evasion and cell-specific immune response WP5039,0.30804683854228365,1.595434131736527,1.8786291694488844,"['IFNAR2', 'CXCL17', 'IRF7']",0.7051175218161021,0,0,3
176,Common Pathways Underlying Drug Addiction WP2636,0.32354919209831107,1.5469515514425694,1.7455864955393536,"['CAMK4', 'GRM1', 'GRIA4']",0.7051175218161021,0,0,3
177,Cell migration and invasion through p75NTR WP4561,0.32725171845197193,1.7907324364723467,2.0002940155050877,"['EFNB3', 'PARD3']",0.7051175218161021,0,0,2
178,EPO Receptor Signaling WP581,0.32725171845197193,1.7907324364723467,2.0002940155050877,"['IRS1', 'IRS2']",0.7051175218161021,0,0,2
179,miRNAs involvement in the immune response in sepsis WP4329,0.32725171845197193,1.7907324364723467,2.0002940155050877,"['IRF7', 'TAB2']",0.7051175218161021,0,0,2
180,SARS-CoV-2 mitochondrial interactions WP5038,0.32725171845197193,1.7907324364723467,2.0002940155050877,"['IFIH1', 'IRF7']",0.7051175218161021,0,0,2
181,Sphingolipid Metabolism (integrated pathway) WP4726,0.32725171845197193,1.7907324364723467,2.0002940155050877,"['UGT8', 'UGCG']",0.7051175218161021,0,0,2
182,TLR4 Signaling and Tolerance WP3851,0.32725171845197193,1.7907324364723467,2.0002940155050877,"['IRF7', 'TAB2']",0.7051175218161021,0,0,2
183,Trans-sulfuration and one-carbon metabolism WP2525,0.32725171845197193,1.7907324364723467,2.0002940155050877,"['BHMT', 'GCLM']",0.7051175218161021,0,0,2
184,Wnt signaling in kidney disease WP4150,0.32725171845197193,1.7907324364723467,2.0002940155050877,"['WNT7B', 'WNT7A']",0.7051175218161021,0,0,2
185,Cholesterol Biosynthesis with Skeletal Dysplasias WP4804,0.3299811062686192,2.834328358208955,3.1424761968882784,['DHCR24'],0.7051175218161021,0,0,1
186,Development of pulmonary dendritic cells and macrophage subsets WP3892,0.3299811062686192,2.834328358208955,3.1424761968882784,['CSF1'],0.7051175218161021,0,0,1
187,Methionine metabolism leading to sulfur amino acids and related disorders WP4292,0.3299811062686192,2.834328358208955,3.1424761968882784,['BHMT'],0.7051175218161021,0,0,1
188,Nanoparticle triggered regulated necrosis WP2513,0.3299811062686192,2.834328358208955,3.1424761968882784,['TNFRSF1A'],0.7051175218161021,0,0,1
189,Osteoclast Signaling WP12,0.3299811062686192,2.834328358208955,3.1424761968882784,['TNFRSF11B'],0.7051175218161021,0,0,1
190,Vitamin B12 Disorders WP4271,0.3299811062686192,2.834328358208955,3.1424761968882784,['CUBN'],0.7051175218161021,0,0,1
191,TGF-beta Receptor Signaling WP560,0.3390523793297602,1.5013208876364916,1.6238296813157331,"['SMAD1', 'EGF', 'SMAD9']",0.72070819899415,0,0,3
192,Overview of leukocyte-intrinsic Hippo pathway functions WP4542,0.347945277550341,1.7010463378176384,1.795811731345018,"['NDRG1', 'TEAD3']",0.735759284819992,0,0,2
193,Focal Adhesion WP306,0.3599693883374756,1.1878381226726622,1.213657308910666,"['EGF', 'ACTN1', 'HGF', 'FLNA', 'PIK3CD', 'LAMB1', 'MYL12A', 'VEGFA', 'IGF1R']",0.7368411139373999,0,0,9
194,Biomarkers for urea cycle disorders WP4583,0.36724751603553474,2.4292110874200428,2.433387454262872,['GLS2'],0.7368411139373999,0,0,1
195,Cancer immunotherapy by CTLA4 blockade WP4582,0.36724751603553474,2.4292110874200428,2.433387454262872,['PIK3CD'],0.7368411139373999,0,0,1
196,Development and heterogeneity of the ILC family WP3893,0.36724751603553474,2.4292110874200428,2.433387454262872,['IL18'],0.7368411139373999,0,0,1
197,Ethanol metabolism resulting in production of ROS by CYP2E1 WP4269,0.36724751603553474,2.4292110874200428,2.433387454262872,['PRKCQ'],0.7368411139373999,0,0,1
198,Galanin receptor pathway WP4970,0.36724751603553474,2.4292110874200428,2.433387454262872,['VEGFA'],0.7368411139373999,0,0,1
199,Major receptors targeted by epinephrine and norepinephrine WP4589,0.36724751603553474,2.4292110874200428,2.433387454262872,['ADCY2'],0.7368411139373999,0,0,1
200,Mammary gland development pathway - Puberty (Stage 2 of 4) WP2814,0.36724751603553474,2.4292110874200428,2.433387454262872,['EGF'],0.7368411139373999,0,0,1
201,Thiamine metabolic pathways WP4297,0.36724751603553474,2.4292110874200428,2.433387454262872,['SLC19A2'],0.7368411139373999,0,0,1
202,Trans-sulfuration pathway WP2333,0.36724751603553474,2.4292110874200428,2.433387454262872,['GCLM'],0.7368411139373999,0,0,1
203,Oxidation by Cytochrome P450 WP43,0.36842055696869996,1.6199017723681401,1.6175208010275017,"['CYP39A1', 'CYP3A7']",0.7368411139373999,0,0,2
204,Parkin-Ubiquitin Proteasomal System pathway WP2359,0.3787510979080746,1.3087302502594858,1.2706148210694133,"['PSMD10', 'RNF19A', 'HSPA1B', 'HSPA1A']",0.7460835528897662,0,0,4
205,Toll-like Receptor Signaling Pathway WP75,0.3787510979080746,1.3087302502594858,1.2706148210694133,"['IFNAR2', 'IRF7', 'PIK3CD', 'TAB2']",0.7460835528897662,0,0,4
206,Senescence and Autophagy in Cancer WP615,0.38274997900591007,1.2511040452216924,1.2015269196708838,"['CEBPB', 'IRF7', 'COL10A1', 'CD44', 'IGF1R']",0.7460835528897662,0,0,5
207,Myometrial relaxation and contraction pathways WP289,0.3849594697538636,1.1912650602409638,1.137202144381978,"['RGS4', 'ACTA2', 'RGS17', 'GRK5', 'PLCG2', 'PRKCQ', 'ADCY2']",0.7460835528897662,0,0,7
208,Cytosolic DNA-sensing pathway WP4655,0.385327279581667,1.3792280304256352,1.3153176777529714,"['RNF125', 'IL18', 'IRF7']",0.7460835528897662,0,0,3
209,Oxysterols derived from cholesterol WP4545,0.3886379023906358,1.546133985595869,1.461262379035773,"['CYP39A1', 'DBP']",0.7460835528897662,0,0,2
210,Sphingolipid pathway WP1422,0.3886379023906358,1.546133985595869,1.461262379035773,"['UGT8', 'UGCG']",0.7460835528897662,0,0,2
211,MECP2 and Associated Rett Syndrome WP3584,0.39155429561349425,1.2839240756980002,1.2038471267910795,"['CEBPD', 'BCL6', 'IGF1R', 'GRIA4']",0.7460835528897662,0,0,4
212,Male infertility WP4673,0.3939490566454883,1.2328632980806893,1.148453679940814,"['NQO1', 'BHMT', 'MSH5', 'PON1', 'FAS']",0.7460835528897662,0,0,5
213,TGF-beta receptor signaling in skeletal dysplasias WP4816,0.4006012836941242,1.342814371257485,1.228391347664995,"['SMAD1', 'EGF', 'SMAD9']",0.7460835528897662,0,0,3
214,15q13.3 copy number variation syndrome WP4942,0.4024440839479281,2.1253731343283584,1.9345127430253755,['SERPINH1'],0.7460835528897662,0,0,1
215,"GPCRs, Class C Metabotropic glutamate, pheromone WP501",0.4024440839479281,2.1253731343283584,1.9345127430253755,['GRM1'],0.7460835528897662,0,0,1
216,MFAP5-mediated ovarian cancer cell motility and invasiveness WP3301,0.4024440839479281,2.1253731343283584,1.9345127430253755,['PRKCQ'],0.7460835528897662,0,0,1
217,NLR Proteins WP288,0.4024440839479281,2.1253731343283584,1.9345127430253755,['ERBIN'],0.7460835528897662,0,0,1
218,NO metabolism in cystic fibrosis WP4947,0.4024440839479281,2.1253731343283584,1.9345127430253755,['PRMT8'],0.7460835528897662,0,0,1
219,Peptide GPCRs WP24,0.4024440839479281,2.1253731343283584,1.9345127430253755,['EDNRA'],0.7460835528897662,0,0,1
220,Wnt signaling WP428,0.4051308514205225,1.2151437151437152,1.0979372396933453,"['DAAM1', 'WIF1', 'WNT7B', 'WNT7A', 'NFATC1']",0.7476505712578734,0,0,5
221,T-cell receptor (TCR) signaling pathway WP69,0.4170315221055272,1.2370178547090092,1.0818877348612543,"['FAS', 'PRKCQ', 'NFATC1', 'MAP3K14']",0.7624498181251369,0,0,4
222,Regulation of Actin Cytoskeleton WP51,0.4218544146331764,1.1450417052826691,0.9882797860669128,"['MRAS', 'FGF9', 'EGF', 'ACTN1', 'PIK3CD', 'PIK3C2A', 'FGFR3']",0.7624498181251369,0,0,7
223,Kisspeptin/kisspeptin receptor system in the ovary WP4871,0.4281650825958374,1.4170403587443947,1.201999454897882,"['PIK3CD', 'PRKCQ']",0.7624498181251369,0,0,2
224,Novel intracellular components of RIG-I-like receptor (RLR) pathway WP3865,0.4308065904857443,1.2754491017964071,1.0740506321911971,"['IFIH1', 'RNF125', 'IRF7']",0.7624498181251369,0,0,3
225,Synaptic signaling pathways associated with autism spectrum disorder WP4539,0.4308065904857443,1.2754491017964071,1.0740506321911971,"['CAMK4', 'PIK3CD', 'GRM1']",0.7624498181251369,0,0,3
226,Epithelial to mesenchymal transition in colorectal cancer WP4239,0.43472253506111624,1.1466756779589422,0.9552350796101691,"['CLDN20', 'NOTCH1', 'WNT7B', 'EIF5A2', 'PIK3CD', 'WNT7A']",0.7624498181251369,0,0,6
227,Bone morphogenic protein (BMP) signaling and regulation WP1425,0.4356856103572211,1.8890547263681592,1.5694915989494849,['SMAD1'],0.7624498181251369,0,0,1
228,Ganglio Sphingolipid Metabolism WP1423,0.4356856103572211,1.8890547263681592,1.5694915989494849,['ST8SIA1'],0.7624498181251369,0,0,1
229,Glutathione metabolism WP100,0.4356856103572211,1.8890547263681592,1.5694915989494849,['GCLM'],0.7624498181251369,0,0,1
230,Osteopontin Signaling WP1434,0.4356856103572211,1.8890547263681592,1.5694915989494849,['MAP3K14'],0.7624498181251369,0,0,1
231,Overview of nanoparticle effects WP3287,0.4356856103572211,1.8890547263681592,1.5694915989494849,['PIK3CD'],0.7624498181251369,0,0,1
232,Pathways of nucleic acid metabolism and innate immune sensing WP4705,0.4356856103572211,1.8890547263681592,1.5694915989494849,['IFIH1'],0.7624498181251369,0,0,1
233,Ras signaling WP4223,0.4445860282643332,1.1062796600816687,0.8967632396426802,"['MRAS', 'PLCG2', 'PLCE1', 'PIK3CD', 'PLA2G5', 'ETS1', 'FGFR3', 'IGF1R']",0.7686395421942478,0,0,8
234,RANKL/RANK signaling pathway WP2018,0.4457038762990803,1.244231050094932,1.0054637361407024,"['TNFRSF11B', 'NFATC1', 'TAB2']",0.7686395421942478,0,0,3
235,Host-pathogen interaction of human coronaviruses - interferon induction WP4880,0.4474192316051831,1.360239162929746,1.0939849230002077,"['IFIH1', 'IFNAR2']",0.7686395421942478,0,0,2
236,Neural Crest Cell Migration during Development WP4564,0.4474192316051831,1.360239162929746,1.0939849230002077,"['PIK3CD', 'EPHB1']",0.7686395421942478,0,0,2
237,Non-small cell lung cancer WP4255,0.4547511662555242,1.1727239828361682,0.9241122412797516,"['EGF', 'PLCG2', 'PIK3CD', 'RXRG']",0.7686395421942478,0,0,4
238,Prolactin Signaling Pathway WP2037,0.4547511662555242,1.1727239828361682,0.9241122412797516,"['SOCS3', 'IRS1', 'FLNA', 'IRS2']",0.7686395421942478,0,0,4
239,ncRNAs involved in Wnt signaling in hepatocellular carcinoma WP4336,0.460443734984646,1.2144995722840035,0.9419228910044508,"['WIF1', 'WNT7B', 'WNT7A']",0.7686395421942478,0,0,3
240,Regulation of toll-like receptor signaling pathway WP1449,0.4604923286134305,1.1336336336336337,0.8790864971401091,"['IFNAR2', 'IRAK2', 'IRF7', 'PIK3CD', 'TAB2']",0.7686395421942478,0,0,5
241,Allograft Rejection WP2328,0.4663032926891779,1.30780728987007,0.9977510479354904,"['FAS', 'VEGFA']",0.7686395421942478,0,0,2
242,Folate Metabolism WP176,0.4663032926891779,1.30780728987007,0.9977510479354904,"['SERPINA3', 'CSF1']",0.7686395421942478,0,0,2
243,Mammalian disorder of sexual development WP4842,0.4670805373657833,1.7,1.2941310848034948,['FGF9'],0.7686395421942478,0,0,1
244,MAPK and NFkB signaling pathways inhibited by Yersinia YopJ WP3849,0.4670805373657833,1.7,1.2941310848034948,['MAP3K14'],0.7686395421942478,0,0,1
245,Serotonin and anxiety WP3947,0.4670805373657833,1.7,1.2941310848034948,['GRM1'],0.7686395421942478,0,0,1
246,Type II diabetes mellitus WP1584,0.4670805373657833,1.7,1.2941310848034948,['IRS1'],0.7686395421942478,0,0,1
247,Hepatitis B infection WP4666,0.4676206081822148,1.0920332706974687,0.8300522810853501,"['IFIH1', 'EGR3', 'IRF7', 'PIK3CD', 'FAS', 'NFATC1', 'TAB2']",0.7686395421942478,0,0,7
248,Development of ureteric collection system WP5053,0.48479888285393324,1.2592592592592593,0.9117303352411879,"['SMAD1', 'SPRY1']",0.791946528488893,0,0,2
249,Integrated breast cancer pathway WP1984,0.48570119604368067,1.072167046564637,0.7742779417762838,"['BARD1', 'SMAD1', 'ITPKC', 'RASGEF1A', 'IRS1', 'FILIP1', 'VEGFA']",0.791946528488893,0,0,7
250,Cardiac Hypertrophic Response WP2795,0.4893970726876055,1.1590909090909092,0.8282644677398127,"['EGF', 'MAP3K14', 'TNFRSF1A']",0.7947808460446714,0,0,3
251,Cell-type Dependent Selectivity of CCK2R Signaling WP3679,0.4967313007198124,1.5453188602442334,1.0812689425570625,['CD38'],0.7949338530939205,0,0,1
252,Eicosanoid metabolism via lipooxygenases (LOX) WP4721,0.4967313007198124,1.5453188602442334,1.0812689425570625,['ALOX12'],0.7949338530939205,0,0,1
253,Pyrimidine metabolism and related diseases WP4225,0.4967313007198124,1.5453188602442334,1.0812689425570625,['GLS2'],0.7949338530939205,0,0,1
254,Neural Crest Cell Migration in Cancer WP4565,0.5028907989667284,1.214178945120649,0.8346050332492747,"['PIK3CD', 'EPHB1']",0.7949338530939205,0,0,2
255,Prader-Willi and Angelman Syndrome WP3998,0.5028907989667284,1.214178945120649,0.8346050332492747,"['PCSK1', 'GABRA5']",0.7949338530939205,0,0,2
256,Type 2 papillary renal cell carcinoma WP4241,0.5028907989667284,1.214178945120649,0.8346050332492747,"['EGLN3', 'VEGFA']",0.7949338530939205,0,0,2
257,MicroRNAs in cardiomyocyte hypertrophy WP1544,0.5036923455806294,1.096677467717754,0.7520900268442812,"['EGF', 'PIK3CD', 'MAP3K14', 'IGF1R']",0.7949338530939205,0,0,4
258,Amino Acid metabolism WP3925,0.5156280981890996,1.0791746983651032,0.7148124197240128,"['ARG2', 'BHMT', 'OAT', 'GCLM']",0.7949338530939205,0,0,4
259,Pathways Regulating Hippo Signaling WP4540,0.5156280981890996,1.0791746983651032,0.7148124197240128,"['PRKCQ', 'FGFR3', 'IGF1R', 'TEAD3']",0.7949338530939205,0,0,4
260,Regulatory circuits of the STAT3 signaling pathway WP4538,0.5175701248295501,1.1085003905233013,0.730069726095976,"['IFNAR2', 'SOCS3', 'OSMR']",0.7949338530939205,0,0,3
261,mBDNF and proBDNF regulation of GABA neurotransmission WP4829,0.5205667222104442,1.1722076181640122,0.7652607515195402,"['GABRA2', 'GABRA5']",0.7949338530939205,0,0,2
262,Airway smooth muscle cell contraction WP4962,0.5247346616482037,1.4164179104477612,0.9133948663558511,['CD38'],0.7949338530939205,0,0,1
263,Canonical and non-canonical TGF-B signaling WP3874,0.5247346616482037,1.4164179104477612,0.9133948663558511,['LOXL2'],0.7949338530939205,0,0,1
264,MAP3K1 role in promoting and blocking gonadal determination WP4872,0.5247346616482037,1.4164179104477612,0.9133948663558511,['FGF9'],0.7949338530939205,0,0,1
265,Omega-3/Omega-6 FA synthesis WP4723,0.5247346616482037,1.4164179104477612,0.9133948663558511,['PLA2G5'],0.7949338530939205,0,0,1
266,PPAR-alpha pathway WP2878,0.5247346616482037,1.4164179104477612,0.9133948663558511,['DBI'],0.7949338530939205,0,0,1
267,Regulation of apoptosis by parathyroid hormone-related protein WP3872,0.5247346616482037,1.4164179104477612,0.9133948663558511,['BCL2L14'],0.7949338530939205,0,0,1
268,Simplified Interaction Map Between LOXL4 and Oxidative Stress Pathway WP3670,0.5247346616482037,1.4164179104477612,0.9133948663558511,['NQO1'],0.7949338530939205,0,0,1
269,Corticotropin-releasing hormone signaling pathway WP2355,0.5274290433015506,1.0622188905547227,0.6795449091371495,"['HSP90AA1', 'IL18', 'PLCG2', 'PRKCQ']",0.7960453218603328,0,0,4
270,Amyotrophic lateral sclerosis (ALS) WP2447,0.5378169448889353,1.133034379671151,0.7027498761044422,"['SLC1A2', 'TNFRSF1A']",0.805733135147261,0,0,2
271,Hepatitis C and Hepatocellular Carcinoma WP3646,0.5378169448889353,1.133034379671151,0.7027498761044422,"['CD44', 'VEGFA']",0.805733135147261,0,0,2
272,Nonalcoholic fatty liver disease WP4396,0.5473834661402973,1.0079385337962017,0.6073894927924556,"['SOCS3', 'XBP1', 'IRS1', 'PIK3CD', 'FAS', 'IRS2', 'TNFRSF1A']",0.8158536391715634,0,0,7
273,Hippo-Merlin Signaling Dysregulation WP4541,0.5506007318547004,1.0298487120076325,0.6145574373849964,"['FGFR3', 'CD44', 'IGF1R', 'TEAD3']",0.8158536391715634,0,0,4
274,Wnt signaling pathway and pluripotency WP399,0.5506007318547004,1.0298487120076325,0.6145574373849964,"['WNT7B', 'WNT7A', 'PRKCQ', 'CD44']",0.8158536391715634,0,0,4
275,Circadian rhythm related genes WP3594,0.5644364823233387,0.9909638554216867,0.5667594030922093,"['EGR3', 'DBP', 'NOCT', 'ID3', 'FAS', 'CARTPT', 'CIART']",0.8324585216545382,0,0,7
276,Mechanoregulation and pathology of YAP/TAZ via Hippo and non-Hippo mechanisms WP4534,0.5710130256499695,1.06203288490284,0.5951029663940276,"['ACTA2', 'TEAD3']",0.8324585216545382,0,0,2
277,MET in type 1 papillary renal cell carcinoma WP4205,0.5712765666082388,1.0194610778443114,0.570777735668973,"['HGF', 'PIK3CD', 'ETS1']",0.8324585216545382,0,0,3
278,Constitutive Androstane Receptor Pathway WP2875,0.5761597157264168,1.2138592750533048,0.6692860406185761,['HSP90AA1'],0.8324585216545382,0,0,1
279,Eicosanoid metabolism via cyclooxygenases (COX) WP4719,0.5761597157264168,1.2138592750533048,0.6692860406185761,['PLA2G5'],0.8324585216545382,0,0,1
280,Overview of interferons-mediated signaling pathway WP4558,0.5761597157264168,1.2138592750533048,0.6692860406185761,['IFNAR2'],0.8324585216545382,0,0,1
281,Statin inhibition of cholesterol production WP430,0.5761597157264168,1.2138592750533048,0.6692860406185761,['APOC1'],0.8324585216545382,0,0,1
282,LncRNA involvement in canonical Wnt signaling and colorectal cancer WP4258,0.5841117123864465,0.9993835857696372,0.5373316029737971,"['WIF1', 'WNT7B', 'WNT7A']",0.8409551603861606,0,0,3
283,22q11.2 copy number variation syndrome WP4657,0.5950705955483889,0.9706575283786678,0.503844282215341,"['ACTA2', 'OAT', 'THAP7', 'HES1']",0.8416803746621631,0,0,4
284,Cardiac Progenitor Differentiation WP2406,0.599749298985702,1.1328358208955225,0.5791550022318855,['NOTCH1'],0.8416803746621631,0,0,1
285,Gastric Cancer Network 1 WP2361,0.599749298985702,1.1328358208955225,0.5791550022318855,['NOTCH1'],0.8416803746621631,0,0,1
286,Nucleotide metabolism WP404,0.599749298985702,1.1328358208955225,0.5791550022318855,['SAT1'],0.8416803746621631,0,0,1
287,Proteoglycan biosynthesis WP4784,0.599749298985702,1.1328358208955225,0.5791550022318855,['XYLT1'],0.8416803746621631,0,0,1
288,"Relationship between inflammation, COX-2 and EGFR WP4483",0.599749298985702,1.1328358208955225,0.5791550022318855,['PIK3CD'],0.8416803746621631,0,0,1
289,Transcription co-factors SKI and SKIL protein partners WP4533,0.599749298985702,1.1328358208955225,0.5791550022318855,['TEAD3'],0.8416803746621631,0,0,1
290,Hedgehog Signaling Pathway WP4249,0.602444534480861,0.9993845071660952,0.5064477698583532,"['HHIP', 'BOC']",0.8416803746621631,0,0,2
291,Thyroid stimulating hormone (TSH) signaling pathway WP2032,0.6090362952940462,0.961501525251384,0.4767868907296005,"['APEX1', 'ADCY2', 'IGF1R']",0.8416803746621631,0,0,3
292,Hypothesized Pathways in Pathogenesis of Cardiovascular Disease WP3668,0.6220278049220203,1.0619402985074626,0.5041779103458458,['FLNA'],0.8416803746621631,0,0,1
293,Inhibition of exosome biogenesis and secretion by Manumycin A in CRPC cells WP4301,0.6220278049220203,1.0619402985074626,0.5041779103458458,['MRAS'],0.8416803746621631,0,0,1
294,Kallmann's Syndrome WP5074,0.6220278049220203,1.0619402985074626,0.5041779103458458,['PRKCQ'],0.8416803746621631,0,0,1
295,Methionine De Novo and Salvage Pathway WP3580,0.6220278049220203,1.0619402985074626,0.5041779103458458,['BHMT'],0.8416803746621631,0,0,1
296,NAD+ biosynthetic pathways WP3645,0.6220278049220203,1.0619402985074626,0.5041779103458458,['CD38'],0.8416803746621631,0,0,1
297,One-carbon metabolism WP241,0.6220278049220203,1.0619402985074626,0.5041779103458458,['BHMT'],0.8416803746621631,0,0,1
298,Sleep regulation WP3591,0.6220278049220203,1.0619402985074626,0.5041779103458458,['IL18'],0.8416803746621631,0,0,1
299,Glycogen Synthesis and Degradation WP500,0.632104590658661,0.9436970602889886,0.4328742256194272,"['HKDC1', 'GYG2']",0.8416803746621631,0,0,2
300,IL-3 signaling pathway WP286,0.632104590658661,0.9436970602889886,0.4328742256194272,"['PIK3CD', 'ENPP3']",0.8416803746621631,0,0,2
301,One-carbon metabolism and related pathways WP3940,0.632104590658661,0.9436970602889886,0.4328742256194272,"['BHMT', 'GCLM']",0.8416803746621631,0,0,2
302,T-Cell antigen Receptor (TCR) pathway during Staphylococcus aureus infection WP3863,0.632104590658661,0.9436970602889886,0.4328742256194272,"['PRKCQ', 'MAP3K14']",0.8416803746621631,0,0,2
303,Endometrial cancer WP4155,0.6329440725910775,0.9263745236799129,0.42369889296490626,"['EGF', 'PIK3CD', 'FGFR3']",0.8416803746621631,0,0,3
304,Proteasome Degradation WP183,0.6329440725910775,0.9263745236799129,0.42369889296490626,"['PSMD10', 'H2AFZ', 'NEDD4']",0.8416803746621631,0,0,3
305,Chemokine signaling pathway WP3929,0.64173694680799,0.9127676063159934,0.40488253343584985,"['GRK5', 'PARD3', 'PIK3CD', 'PRKX', 'ADCY2']",0.8416803746621631,0,0,5
306,Gastric Cancer Network 2 WP2363,0.6430679986814941,0.9993854258121159,0.4412334706507253,['S100A6'],0.8416803746621631,0,0,1
307,Genes controlling nephrogenesis WP4823,0.6430679986814941,0.9993854258121159,0.4412334706507253,['VEGFA'],0.8416803746621631,0,0,1
308,Hematopoietic Stem Cell Gene Regulation by GABP alpha/beta Complex WP3657,0.6430679986814941,0.9993854258121159,0.4412334706507253,['ETV6'],0.8416803746621631,0,0,1
309,Immune response to tuberculosis WP4197,0.6430679986814941,0.9993854258121159,0.4412334706507253,['IFNAR2'],0.8416803746621631,0,0,1
310,Phosphodiesterases in neuronal function WP4222,0.6462743426382555,0.9181109360481557,0.40078405610809287,"['ADCY2', 'PDE8B']",0.8416803746621631,0,0,2
311,Regulation of Microtubule Cytoskeleton WP2038,0.6462743426382555,0.9181109360481557,0.40078405610809287,"['PARD6A', 'CAMK4']",0.8416803746621631,0,0,2
312,ErbB signaling pathway WP673,0.6468085637797903,0.9055472263868066,0.39455137380443533,"['NRG4', 'EGF', 'PLCG2', 'PIK3CD']",0.8416803746621631,0,0,4
313,Modulators of TCR signaling and T cell activation WP5072,0.6600083862318081,0.8938714499252616,0.3714060345337452,"['PRKCQ', 'MAP3K14']",0.846393322792702,0,0,2
314,7-oxo-C and 7beta-HC pathways WP5064,0.6629386124336927,0.9437810945273631,0.38796281609078215,['DBP'],0.846393322792702,0,0,1
315,Fibrin Complement Receptor 3 Signaling Pathway WP4136,0.6629386124336927,0.9437810945273631,0.38796281609078215,['IRAK2'],0.846393322792702,0,0,1
316,Glycerolipids and Glycerophospholipids WP4722,0.6629386124336927,0.9437810945273631,0.38796281609078215,['PNPLA3'],0.846393322792702,0,0,1
317,Hereditary leiomyomatosis and renal cell carcinoma pathway WP4206,0.6629386124336927,0.9437810945273631,0.38796281609078215,['VEGFA'],0.846393322792702,0,0,1
318,Wnt/beta-catenin signaling pathway in leukemia WP3658,0.6629386124336927,0.9437810945273631,0.38796281609078215,['WIF1'],0.846393322792702,0,0,1
319,Retinoblastoma gene in cancer WP2446,0.6668637294954767,0.8782263060086724,0.35583056382931666,"['BARD1', 'H2AFZ', 'RBP1']",0.8487356557215158,0,0,3
320,Energy Metabolism WP1541,0.6733113019026788,0.8708750143727723,0.34447243277666895,"['CAMK4', 'TFB2M']",0.8489577284859864,0,0,2
321,Envelope proteins and their potential roles in EDMD physiopathology WP4535,0.6733113019026788,0.8708750143727723,0.34447243277666895,"['ADCY2', 'SYNE2']",0.8489577284859864,0,0,2
322,"GPCRs, Class A Rhodopsin-like WP455",0.6733113019026788,0.8708750143727723,0.34447243277666895,"['EDNRA', 'ACKR4']",0.8489577284859864,0,0,2
323,Extracellular vesicle-mediated signaling in recipient cells WP2870,0.6817045689848631,0.8940298507462686,0.3425554926559637,['HGF'],0.8516063231010904,0,0,1
324,Fatty Acid Biosynthesis WP357,0.6817045689848631,0.8940298507462686,0.3425554926559637,['ACSL6'],0.8516063231010904,0,0,1
325,Toll-like Receptor Signaling related to MyD88 WP3858,0.6817045689848631,0.8940298507462686,0.3425554926559637,['IRF7'],0.8516063231010904,0,0,1
326,Endoplasmic reticulum stress response in coronavirus infection WP4861,0.686188507008881,0.8490284005979073,0.31974655567945587,"['XBP1', 'PPP1R3C']",0.8544301746549328,0,0,2
327,Thyroid hormones production and their peripheral downstream signaling effects WP4746,0.6881740569265099,0.8488023952095808,0.31720889976967565,"['SLCO1C1', 'NOTCH1', 'PRKCQ']",0.8544301746549328,0,0,3
328,Synaptic Vesicle Pathway WP2267,0.6986461484357694,0.8282474752998651,0.2970185645370282,"['SNAP25', 'SLC22A3']",0.855323614792454,0,0,2
329,Oxidative Stress WP408,0.6994271923918589,0.8492537313432836,0.30360275293243877,['NQO1'],0.855323614792454,0,0,1
330,Photodynamic therapy-induced unfolded protein response WP3613,0.6994271923918589,0.8492537313432836,0.30360275293243877,['XBP1'],0.855323614792454,0,0,1
331,Pre-implantation embryo WP3527,0.6994271923918589,0.8492537313432836,0.30360275293243877,['ZFP36'],0.855323614792454,0,0,1
332,Type II interferon signaling (IFNG) WP619,0.6994271923918589,0.8492537313432836,0.30360275293243877,['SOCS3'],0.855323614792454,0,0,1
333,Ectoderm Differentiation WP2858,0.7089211342333994,0.8398745279933398,0.2889260710850678,"['BOC', 'RHPN1', 'TNFRSF11B', 'NFATC1', 'KIFC3']",0.8623503317177321,0,0,5
334,Selenium Micronutrient Network WP15,0.7106910053274539,0.8084561178731582,0.27610194077783495,"['SERPINA3', 'SEPHS2']",0.8623503317177321,0,0,2
335,Gastrin signaling pathway WP4659,0.7115452244468972,0.8277324752258017,0.2816908544796845,"['IRS1', 'PRKCQ', 'CD44', 'VEGFA']",0.8623503317177321,0,0,4
336,Leptin signaling pathway WP2034,0.7181965242594037,0.808169375534645,0.2675137910089587,"['SOCS3', 'IRS1', 'PLCG2']",0.8678208001467794,0,0,3
337,MTHFR deficiency WP4288,0.7319709260078647,0.7719131614654002,0.24084808705931096,['BHMT'],0.8818403440925612,0,0,1
338,B Cell Receptor Signaling Pathway WP23,0.7459277971008897,0.7712302667392488,0.22606800579338746,"['BCL6', 'PLCG2', 'ETS1']",0.8866688952323376,0,0,3
339,16p11.2 distal deletion syndrome WP4950,0.7468984289888164,0.7382868267358857,0.21545134686821926,['PLN'],0.8866688952323376,0,0,1
340,Glycerophospholipid Biosynthetic Pathway WP2533,0.7468984289888164,0.7382868267358857,0.21545134686821926,['PIK3CD'],0.8866688952323376,0,0,1
341,Nanoparticle-mediated activation of receptor signaling WP2643,0.7468984289888164,0.7382868267358857,0.21545134686821926,['PIK3CD'],0.8866688952323376,0,0,1
342,Photodynamic therapy-induced HIF-1 survival signaling WP3614,0.7468984289888164,0.7382868267358857,0.21545134686821926,['VEGFA'],0.8866688952323376,0,0,1
343,Small cell lung cancer WP4658,0.7546737741254513,0.7596523371168111,0.21381912330314726,"['PIK3CD', 'LAMB1', 'RXRG']",0.8909522761243666,0,0,3
344,DNA damage response WP707,0.7548955245979854,0.7378956261779425,0.20747847958005866,"['SESN1', 'FAS']",0.8909522761243666,0,0,2
345,AGE/RAGE pathway WP2324,0.764994463841877,0.7221321120758197,0.19344957546227123,"['LGALS3', 'IRS1']",0.9002543545501508,0,0,2
346,Nuclear receptors WP170,0.7743089355964942,0.6791044776119403,0.17370429292681172,['RXRG'],0.9012619538577331,0,0,1
347,Oxidative Damage WP3941,0.7743089355964942,0.6791044776119403,0.17370429292681172,['C1R'],0.9012619538577331,0,0,1
348,Renin-angiotensin-aldosterone system (RAAS) WP4756,0.7743089355964942,0.6791044776119403,0.17370429292681172,['CAMK4'],0.9012619538577331,0,0,1
349,miRNA regulation of DNA damage response WP1530,0.7747301031929775,0.7070254110612855,0.18046156484269074,"['SESN1', 'FAS']",0.9012619538577331,0,0,2
350,Pancreatic adenocarcinoma pathway WP4263,0.7794618408093893,0.7269033361847733,0.18110908935038406,"['EGF', 'PIK3CD', 'VEGFA']",0.9041757353388915,0,0,3
351,Primary focal segmental glomerulosclerosis (FSGS) WP2572,0.7841115571825291,0.6925353100881608,0.1684273412313934,"['NOTCH1', 'PLCE1']",0.9050252920345013,0,0,2
352,Base Excision Repair WP4752,0.7868815962763028,0.6529276693455798,0.15649206581633676,['APEX1'],0.9050252920345013,0,0,1
353,Intraflagellar transport proteins binding to dynein WP4532,0.7868815962763028,0.6529276693455798,0.15649206581633676,['IFT27'],0.9050252920345013,0,0,1
354,Mesodermal commitment pathway WP2857,0.801505273424163,0.7212989250055823,0.1595972887959992,"['SMAD1', 'SESN1', 'HMGA2', 'TBX6']",0.9144681032714043,0,0,4
355,AMP-activated protein kinase (AMPK) signaling WP1403,0.801848878730591,0.6652598259034556,0.14691273307301686,"['CRTC2', 'PIK3CD']",0.9144681032714043,0,0,2
356,Pathways affected in adenoid cystic carcinoma WP3651,0.801848878730591,0.6652598259034556,0.14691273307301686,"['NOTCH1', 'ERBIN']",0.9144681032714043,0,0,2
357,Fatty acid beta-oxidation WP143,0.8099675389824837,0.6061833688699361,0.1277598781401674,['ACSL6'],0.9211395541369423,0,0,1
358,CAMKK2  Pathway WP4874,0.8205563715227072,0.5852290272774061,0.11574230549839587,['CAMK4'],0.9265059899933772,0,0,1
359,Initiation of transcription and translation elongation at the HIV-1 LTR WP3414,0.8305560059265137,0.5656716417910448,0.10502254938930888,['NFATC1'],0.9265059899933772,0,0,1
360,Signaling of Hepatocyte Growth Factor Receptor WP313,0.8305560059265137,0.5656716417910448,0.10502254938930888,['HGF'],0.9265059899933772,0,0,1
361,TNF related weak inducer of apoptosis (TWEAK) Signaling Pathway WP2036,0.8305560059265137,0.5656716417910448,0.10502254938930888,['MAP3K14'],0.9265059899933772,0,0,1
362,Vitamin D-sensitive calcium signaling in depression WP4698,0.8305560059265137,0.5656716417910448,0.10502254938930888,['ATP2B4'],0.9265059899933772,0,0,1
363,Melanoma WP4685,0.8334819728069538,0.6166598722652534,0.11232040573350792,"['PIK3CD', 'ETS1']",0.9265059899933772,0,0,2
364,Disruption of postsynaptic signaling by CNV WP4875,0.8399991808324905,0.5473760231102551,0.09543739747214953,['GRM1'],0.9265059899933772,0,0,1
365,Host-pathogen interaction of human coronaviruses - MAPK signaling WP4877,0.8399991808324905,0.5473760231102551,0.09543739747214953,['IFITM3'],0.9265059899933772,0,0,1
366,p38 MAPK Signaling Pathway WP400,0.8399991808324905,0.5473760231102551,0.09543739747214953,['HSPB1'],0.9265059899933772,0,0,1
367,Parkinson's disease pathway WP2371,0.8399991808324905,0.5473760231102551,0.09543739747214953,['CASP6'],0.9265059899933772,0,0,1
368,7q11.23 copy number variation syndrome WP4932,0.8416713360922942,0.6435799287500947,0.11093109084584286,"['CLIP2', 'SNAP25', 'FAS']",0.9265059899933772,0,0,3
369,VEGFA-VEGFR2 Signaling Pathway WP3888,0.8465582186016967,0.7922097109981867,0.13196336573605322,"['HSP90AA1', 'EGR3', 'EPB41', 'HSPB1', 'NFATC1', 'NRARP', 'PLA2G5', 'ETS1', 'NDRG1', 'APOLD1', 'VEGFA', 'DNAJA1', 'TXNIP', 'FAS', 'TMSB10', 'HSPA1A']",0.9265059899933772,0,0,16
370,TGF-beta Signaling Pathway WP366,0.8478049696257001,0.6642561072404974,0.1096717776033982,"['KLF6', 'PARD6A', 'LIMK2', 'ETS1']",0.9265059899933772,0,0,4
371,IL-2 signaling pathway WP49,0.8489168184175772,0.530223880597015,0.08684752922848583,['SOCS3'],0.9265059899933772,0,0,1
372,Integrated Cancer Pathway WP1971,0.8489168184175772,0.530223880597015,0.08684752922848583,['BARD1'],0.9265059899933772,0,0,1
373,G13 Signaling Pathway WP524,0.8573381247646382,0.5141112618724559,0.07913349303256531,['PIK3CD'],0.9331884146231719,0,0,1
374,16p11.2 proximal deletion syndrome WP4949,0.8665792148665769,0.5650224215246636,0.08091220218186133,"['MVP', 'TBX6']",0.9400955015350718,0,0,2
375,DNA IR-damage and cellular response via ATR WP4016,0.8724285495416815,0.5557107500796393,0.07584035782129371,"['BARD1', 'BCL6']",0.9400955015350718,0,0,2
376,IL-6 signaling pathway WP364,0.8728005549563362,0.4846481876332623,0.06593551774279473,['SOCS3'],0.9400955015350718,0,0,1
377,Fragile X Syndrome  WP4549,0.8762409113747636,0.6270198234216225,0.08283823042523078,"['CAMK4', 'AKAP5', 'SLC6A1', 'GRM1']",0.9400955015350718,0,0,4
378,Alzheimer's disease WP2059,0.8780410881757013,0.5466994551328415,0.07110476383637608,"['FAS', 'TNFRSF1A']",0.9400955015350718,0,0,2
379,Interleukin-11 Signaling Pathway WP2332,0.8798923413382446,0.4711442786069652,0.06028560463087261,['SOCS3'],0.9400955015350718,0,0,1
380,Netrin-UNC5B signaling pathway WP4747,0.8798923413382446,0.4711442786069652,0.06028560463087261,['UNC5B'],0.9400955015350718,0,0,1
381,EGF/EGFR signaling pathway WP437,0.8918584610411343,0.6311908923849222,0.07223843107698591,"['PLSCR1', 'EGF', 'LIMK2', 'NEDD4', 'PLCE1']",0.9465347719577398,0,0,5
382,ATM Signaling Network in Development and Disease  WP3878,0.8929133439896906,0.4462686567164179,0.05054695054303953,['HSPB1'],0.9465347719577398,0,0,1
383,Splicing factor NOVA regulated synaptic proteins WP4148,0.8929133439896906,0.4462686567164179,0.05054695054303953,['EPB41'],0.9465347719577398,0,0,1
384,Translation inhibitors in chronically activated PDGFRA cells WP4566,0.8988852455936298,0.43478760045924225,0.0463483144622423,['PDCD4'],0.950383879455765,0,0,1
385,Cholesterol metabolism (includes both Bloch and Kandutsch-Russell pathways) WP4718,0.9045245737591772,0.42388059701492536,0.042534640231798836,['DHCR24'],0.9513911319850412,0,0,1
386,Neurodegeneration with brain iron accumulation (NBIA) subtypes pathway WP4577,0.9045245737591772,0.42388059701492536,0.042534640231798836,['CP'],0.9513911319850412,0,0,1
387,Pathways in clear cell renal cell carcinoma WP4018,0.9071901730808668,0.49819748527213575,0.048526018441346686,"['ENPP3', 'VEGFA']",0.9517292255060256,0,0,2
388,Pyrimidine metabolism WP4022,0.9153623901928769,0.4838778560751655,0.04279185300688419,"['ENTPD3', 'ENPP3']",0.9578276557172888,0,0,2
389,Brain-derived neurotrophic factor (BDNF) signaling pathway WP2380,0.9280417703638848,0.5498226496507843,0.04105995055806539,"['IRS1', 'CAMK4', 'IRS2', 'SH2B2']",0.9670846493651893,0,0,4
390,Androgen receptor signaling pathway WP138,0.9329326139657667,0.4514200298953662,0.031338619386830344,"['LIMK2', 'FLNA']",0.9670846493651893,0,0,2
391,Arrhythmogenic Right Ventricular Cardiomyopathy WP2118,0.9361188847303433,0.36052715147665926,0.02379940565234708,['ACTN1'],0.9670846493651893,0,0,1
392,Kit receptor signaling pathway WP304,0.9361188847303433,0.36052715147665926,0.02379940565234708,['SH2B2'],0.9670846493651893,0,0,1
393,Rett syndrome causing genes WP4312,0.9361188847303433,0.36052715147665926,0.02379940565234708,['SYNE2'],0.9670846493651893,0,0,1
394,Association Between Physico-Chemical Features and Toxicity Associated Pathways WP3680,0.9462290997838144,0.33880597014925373,0.018725996341543167,['DAAM1'],0.9750482601833216,0,0,1
395,Acute viral myocarditis WP4298,0.9492306698808645,0.3321334503950834,0.0173052965162413,['CASP6'],0.9756649417003315,0,0,1
396,3q29 copy number variation syndrome WP4906,0.952064916185858,0.3257175660160735,0.015999916923444338,['PIGM'],0.9761069595238847,0,0,1
397,Thermogenesis WP4321,0.9582476337359376,0.3979600808933439,0.016972617033834507,"['ACSL6', 'ADCY2']",0.9799711317299513,0,0,2
398,Sterol regulatory element-binding proteins (SREBP) signaling WP1982,0.9679402306624142,0.2868960283329117,0.009348489523850836,['DBI'],0.9873963157008547,0,0,1
399,Endoderm differentiation WP2853,0.9742598661100644,0.35575485799701045,0.009277093406743849,"['NOTCH1', 'SESN1']",0.9913521444628727,0,0,2
400,Joubert Syndrome WP4656,0.9808922445421804,0.24872695346795434,0.004798606514654281,['FLNA'],0.995605628210313,0,0,1
401,Ciliopathies WP4803,0.9923020165510679,0.33682634730538924,0.0026029151491412336,"['IFT27', 'PKD1L1', 'CFAP53']",0.9991959170476648,0,0,3
402,Cytoplasmic Ribosomal Proteins WP477,0.9928177283830926,0.1986830553116769,0.001432144874312053,['RPS4Y1'],0.9991959170476648,0,0,1
403,Genes related to primary cilium development (based on CRISPR) WP4536,0.9964023418902591,0.17391906447145714,0.0006268295692903774,['IFT27'],0.9991959170476648,0,0,1
404,DNA Repair Pathways Full Network WP4946,0.9971430469366289,0.1669720703413625,0.0004777140966324645,['APEX1'],0.9991959170476648,0,0,1
405,Ciliary landscape WP4352,0.9990892247362096,0.25806080147397514,0.0002351424917807577,"['CDH23', 'IFT27', 'MAPRE2']",0.9991959170476648,0,0,3
406,mRNA Processing WP411,0.9991959170476648,0.13684018929741537,0.00011007512410690152,['U2AF1'],0.9991959170476648,0,0,1
